AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Harry Ehrlich who wrote (1143)	2/24/1998 11:48:00 PM
From: D.Right	Read Replies (1) of 2173

Dear Harry: How bad does the TA look like? I am sure all the positive momentums are gone. Actrally, as I said earlier, it has nothing to do with AMLN. If it had not been with JNJ, ergo would have gotten somebody else to cut a deal. They have a product and they want to sell it, as simple as that. It happened that JNJ is most interested in diabetes. If you look at the commitment JNJ made with ergo for 50% right and the commitment JNJ made with AMLN for 50% of their product, you would know how much more JNJ is expecting from AMLN. However, because AMLN is in a slump here, ergo got a bigger market cap than AMLN. As you said before, never a dull market. D.Right

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next